Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
MW-150 is an inhibitor of p38α MAPK (Ki = 101 nM).1 It is 6-, 10-, and 14-fold selective for p38α MAPK over the serine/threonine protein kinase NLK, p38β MAPK, and p38δ MAPK, respectively, and is also selective over the enzymatically normal mutant p38α MAPKT106M. It inhibits p38α MAPK phosphorylation of the endogenous substrate MAPK-activated protein kinase 2 (MK2) in LPS-activated glia in a concentration-dependent manner and decreases the levels of IL-1β in the same cells. MW-150 (2.5 mg/kg per day, i.p.) reduces the number of errors made in the spatial reference memory version of the radial arm water maze in aged amyloid precursor protein/presenilin 1 (APP/PS1) knock-in mice as a model of Alzheimer’s disease.
WARNING This product is not for human or veterinary use.
1. Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer’s disease mouse models. ACS Chem. Neurosci. 6(4), 666-680 (2015).